Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERT targeted therapy for advanced colorectal cancer patients
2020-002533-14Phase 4Terminated
- Sponsor
- University of Rome Tor Vergata, Department of Systems Medicine
- Start
- Aug 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of oxaliplatin, irinotecan, cetuximab, panitumumab, capecitabine and 4 more in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by University of Rome Tor Vergata, Department of Systems Medicine. Primary endpoint: Progression-free survival. Started Aug 2021; status: terminated.
02
Drugs
oxaliplatinirinotecancetuximabpanitumumabcapecitabine
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2020-002533-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002533-14.